Loading...

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Title

Showing 1,267 results.

Thumbnail for Population-Level Trends in Sepsis-Related Mortality Among Patients with Multiple Myeloma: Insights from CDC WONDER

MM - 1669

Population-Level Trends in Sepsis-Related Mortality Among Patients with Multiple Myeloma: Insights from CDC WONDER

Amna Bint I Munir

Poster Presenter: Amna Bint I Munir

$Thumbnail for Post-BCMA Sequencing in Relapsed/Refractory Multiple Myeloma: BCMA Re-Targeting Versus Non-BCMA T-Cell Redirection$

MM - 605

Post-BCMA Sequencing in Relapsed/Refractory Multiple Myeloma: BCMA Re-Targeting Versus Non-BCMA T-Cell Redirection

Ayse Gul Korkmaz

Poster Presenter: Ayse Gul Korkmaz

Thumbnail for Post-CAR-T Relapse in DLBCL: Real-World Salvage Therapy Patterns and Outcomes at a Tertiary Academic Center

ABCL - 865

Post-CAR-T Relapse in DLBCL: Real-World Salvage Therapy Patterns and Outcomes at a Tertiary Academic Center

Jivtesh Singh

Poster Presenter: Jivtesh Singh

Thumbnail for Post-Induction Consolidation With Blinatumomab vs Chemotherapy in First-Relapse B-Cell Acute Lymphoblastic Leukemia: Evidence From Randomized Controlled Trials

ALL - 1212

Post-Induction Consolidation With Blinatumomab vs Chemotherapy in First-Relapse B-Cell Acute Lymphoblastic Leukemia: Evidence From Randomized Controlled Trials

Bashar M Al Zoubi

Poster Presenter: Bashar M Al Zoubi

Thumbnail for Post-Transplant Oral Azacitidine Maintenance: Clinical Outcomes and Immune Landscape

AML - 739

Post-Transplant Oral Azacitidine Maintenance: Clinical Outcomes and Immune Landscape

Gabriela Sanchez-Petitto

Poster Presenter: Gabriela Sanchez-Petitto

Thumbnail for Postmarketing Safety Signals of Revumenib (Menin-KMT2A Inhibitor) vs Acute Myeloid Leukemia-Targeted Therapies: A Class-Restricted Disproportionality Analysis of the FDA Adverse Event Monitoring System (2016-2026)

AML - 867

Postmarketing Safety Signals of Revumenib (Menin-KMT2A Inhibitor) vs Acute Myeloid Leukemia-Targeted Therapies: A Class-Restricted Disproportionality Analysis of the FDA Adverse Event Monitoring System (2016-2026)

Arashdeep Singh

Poster Presenter: Arashdeep Singh

Thumbnail for Postransplant Cyclophosphamide Is Associated With Improved Long-Term Survival Following Second Allogeneic Hematopoietic Stem Cell Transplantation: A Large Real-World Propensity Score-Matched Analysis

CT - 1349

Postransplant Cyclophosphamide Is Associated With Improved Long-Term Survival Following Second Allogeneic Hematopoietic Stem Cell Transplantation: A Large Real-World Propensity Score-Matched Analysis

Muzammil Dastagir

Poster Presenter: Muzammil Dastagir

Thumbnail for Pre-CAR-T Antibiotic Exposure and Gut Microbiome Disruption as Predictors of Response and Survival in Hematologic Malignancies: A Systematic Review

CT - 497

Pre-CAR-T Antibiotic Exposure and Gut Microbiome Disruption as Predictors of Response and Survival in Hematologic Malignancies: A Systematic Review

Mary Anusha Chowdary Koka

Poster Presenter: Mary Anusha Chowdary Koka

Thumbnail for Precision Targeting of t(11; 14) Multiple Myeloma With Venetoclax: Evidence From a Systematic Review and Meta-Analysis

MM - 905

Precision Targeting of t(11; 14) Multiple Myeloma With Venetoclax: Evidence From a Systematic Review and Meta-Analysis

Sai Sree Gummadi

Poster Presenter: Sai Sree Gummadi

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.